carbapenems has been researched along with ertapenem in 146 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (ertapenem) | Trials (ertapenem) | Recent Studies (post-2010) (ertapenem) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 850 | 89 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (20.55) | 29.6817 |
| 2010's | 90 (61.64) | 24.3611 |
| 2020's | 26 (17.81) | 2.80 |
| Authors | Studies |
|---|---|
| Odenholt, I | 1 |
| Ashwood, MS; Brands, KM; Cameron, M; Conrad, KM; Cottrell, IF; Davies, AJ; Dolling, UH; Houghton, PG; Jobson, RB; Kennedy, DJ; Pipik, B; Reamer, RA; Reider, PJ; Williams, JM | 1 |
| Goldstein, EJ | 2 |
| Armstrong, SH; Hilliard, NJ; Johnson, CN; Quarles, S; Waites, KB | 1 |
| Livermore, DM; Scott, GM; Sefton, AM | 1 |
| Isaacs, RD; Shah, PM | 1 |
| Birk, K; Deutsch, P; Holland, S; Majumdar, A; Mistry, G; Muckow, J; Musson, DG; Rogers, JD; Sciberras, D; Xi, L | 1 |
| Hammond, ML | 1 |
| Holland, S; Lin, JH; Majumdar, A; Mistry, G; Musson, D; Sahly, Y; Singh, R; Waldman, S; Wong, BK; Xu, X; Yu, S | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Livermore, DM; Mushtaq, S; Warner, M | 1 |
| Embil, JM; Gin, A; Hoban, DJ; Johanson, C; Noreddin, A; Vercaigne, L; Zhanel, GG | 1 |
| Deters, M; Kaever, V; Koal, T; Resch, K | 1 |
| Avlamis, A; Katsandri, A; Legakis, NJ; Pantazatou, A; Papaparaskevas, J | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Hernández, JR; Martínez-Martínez, L; Pascual, A; Romero, L; Velasco, C | 1 |
| Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
| Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
| Dallow, JW; Hill, RL; Livermore, DM; Palepou, MF; Pike, R; Ward, ME; Warner, M; Woodford, N | 1 |
| Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
| Lister, PD | 1 |
| Nicolau, DP | 1 |
| Shah, PM | 1 |
| Joseph, J; Rodvold, KA | 1 |
| Aybey, AD; Dinleyici, EC; Durmaz, G; Erben, N; Kiremitci, A; Usluer, G; Yargic, ZA | 1 |
| Blanchet, B; Chhun, S; Jullien, V; Lanternier, F; Legrand, T; Pons, G; Rey, E; Zahar, JR | 1 |
| Carey, PR; Kalp, M | 1 |
| Dunne, WM; Fraser, VJ; Frye, JG; Marschall, J; Tibbetts, RJ; Warren, DK | 1 |
| Cattoir, V; Daurel, C | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
| Eagye, KJ; Nicolau, DP | 2 |
| Blanchard, JS; Fan, F; Tremblay, LW | 1 |
| dos Santos, RP; Goldani, LZ; Jacoby, T | 1 |
| Ko, WC; Lee, CC; Wu, JJ; Yan, JJ; Yang, FC | 1 |
| Cai, J; Liu, J; Wu, D | 1 |
| Ahmed-Bentley, J; Peirano, G; Pitout, JD; Woodford, N | 1 |
| Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
| Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
| Hsueh, PR; Huang, WH; Ko, WC; Lee, NY; Tsui, KC | 1 |
| Engler, C; Harris, P; Norton, R | 1 |
| Dihmess, A; Evans, A; Fiorenza, M; Graffunder, E; Harrington, S; Lodise, TP; Martis, P; Masoud, R; McNutt, LA; Patel, N; Woo, B | 1 |
| Gastal, SL; Goldani, LZ; Gorniak Lovatto, C; Jacoby, T; Konkewicz, L; Kuplich, NM; Lisboa, T; Nagel, FM; Pires dos Santos, R; Pires Machado, D; Pires, MR | 1 |
| Beović, B; Cizman, M; Kreft, S; Seme, K | 1 |
| Bonomo, RA; Endimiani, A; Papp-Wallace, KM; Taracila, MA | 1 |
| Cook, PP; Gooch, M; Rizzo, S | 1 |
| Carmeli, Y; Crank, CW; Goff, DA; Goldstein, EJ; Graber, CJ; Lima, AL; Nicolau, DP | 1 |
| Chang, SC; Chen, WC; Chen, YC; Hu, FC; Wang, JL; Wu, UI; Yang, CS | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Chiu, CH; Su, LH; Wu, TL | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Cai, Y; Kwa, AL; Lee, W; Tan, TT; Tan, TY; Tang, S; Teo, J | 1 |
| Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Ho, MW; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Tang, HJ; Toh, HS; Wang, JH; Yu, KW | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 2 |
| McDougall, DA; Morton, AP; Playford, EG | 1 |
| Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, CM | 1 |
| Falagas, ME; Kapaskelis, A; Tansarli, GS; Vardakas, KZ | 1 |
| Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
| Debets-Ossenkopp, Y; Murk, JL; Vainio, S; van Doorn-Schepens, M; Vandenbroucke-Grauls, C; Wilhelm, A | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, C | 1 |
| Adler, M; Cars, O; Löwdin, E; Sandegren, L; Tängdén, T | 1 |
| Caio, C; Ceccarelli, G; Falcone, M; Giordano, A; Mezzatesta, ML; Stefani, S; Venditti, M | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 3 |
| Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
| Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
| Farrell, R; Kopacz, J; Mariano, N; Piracha, N; Prasad, N; Segal-Maurer, S; Shakil, J; Tarasuk, A; Urban, C; Wang, G | 1 |
| Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
| Barth, AL; da Silva, RC; Dalarosa, MG; Falci, DR; Luz, DI; Magagnin, CM; Ribeiro, VB; Rozales, FP; Sampaio, JM; Vieira, FJ; Zavascki, AP | 1 |
| Kim, HJ; Kim, MJ; Lee, SE; Sohn, JW; Yang, KS; Yoon, YK | 1 |
| Badal, RE; Biedenbach, DJ; Bouchillon, SK; Hackel, M; Hoban, DJ; Nga, TT; Phuong, DM; Phuong, NT; Phuong, TT | 1 |
| Danishuddin, M; Faheem, M; Khan, A; Khan, AU | 1 |
| Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
| Bai, KJ; Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
| Daitch, V; Farbman, L; Lador, A; Leibovici, L; Paul, M; Tredler, Z; Zusman, O | 1 |
| Amicosante, G; Bottoni, C; Celenza, G; Colapietro, M; Compagnoni, C; Marcoccia, F; Maturo, MG; Perilli, M; Sabatini, A; Segatore, B | 1 |
| Anupurba, S; Banerjee, T; Filgona, J | 1 |
| Cprek, JB; Gallagher, JC | 1 |
| Arora, R; Chakotiya, AS; Chawla, R; Goel, R; Narula, A; Sharma, RK; Tanwar, A; Thakur, P | 1 |
| Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
| Berrio, I; Castro, B; Maldonado, N; Manjarrés, M; Robledo, C; Robledo, J | 1 |
| Cipolla, A; D'Abramo, A; De Angelis, M; Favaro, M; Ferretti, G; Gizzi, F; Iannetta, M; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Vullo, V | 1 |
| Akova, M; Almela, M; Almirante, B; Bermejo, J; Bonomo, RA; Bou, G; Calbo, E; Carmeli, Y; Cisneros, JM; García-Vázquez, E; Gasch, O; Giamarellou, H; Gracia-Ahulfinger, I; Gutiérrez-Gutiérrez, B; Hamprecht, A; Hsueh, PR; Lowman, W; Martínez-Martínez, L; Mora-Rillo, M; Oliver, A; Origüen, J; Pascual, A; Paterson, DL; Peña, C; Pérez, F; Pintado, V; Pitout, J; Prim, N; Rodríguez-Baño, J; Schwaber, MJ; Tacconelli, E; Tumbarello, M; Venditti, M; Viale, P | 1 |
| Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
| Aktaş, Z; Akyön, Y; Aşçı Toraman, Z; Ay, S; Ayaş, R; Aydemir, Ş; Aydın, F; Bakıcı, Z; Bayramoğlu, G; Baysallar, M; Büyüktaş, A; Çağatay, M; Çakar, A; Çelik, C; Çöplü, N; Dündar, D; Erçal, BD; Güdücüoğlu, H; Gülay, Z; Günaydın, M; Gür, D; Hasdemir, U; Karatuna, O; Kayacan, Ç; Kılıç, A; Kılıç, H; Öğünç, D; Özhak Baysan, B; Parlak, M; Tünger, A; Yanık, K; Zer, Y | 1 |
| Hu, Q; Hu, Y; Lin, X; Lv, H; Xu, X; Zhang, R | 1 |
| Burgers, PC; Dekker, LJ; Goessens, WH; Kostzrewa, M; Luider, TM; Monteferrante, CG; Peer, M; Sparbier, K; Sultan, S; Ten Kate, MT | 1 |
| Arai, K; Kashiwa, M; Nagano, N; Saito, R; Yamada, K | 1 |
| Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
| Bhattacharjee, A; Chakravarty, A; Choudhury, NA; Dhar, D; Ingti, B; Maurya, AP; Paul, D | 1 |
| Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
| Jitmuang, A; Kiratisin, P; Rattanaumpawan, P; Thamlikitkul, V; Werarak, P | 1 |
| Fisher, S; Galanis, C; Gupta, C; Kaushik, A; Lamichhane, G; Parrish, N; Story-Roller, E | 1 |
| D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
| Fraser, TG; Jones, JS | 1 |
| Fakhar, Z; Govender, T; Honarparvar, B; Kruger, HG; Lamichhane, G; Maguire, GEM; Walker, RC | 1 |
| Antonelli, M; Arcadipane, A; Capitanio, G; Cutuli, SL; De Pascale, G; Di Carlo, D; Di Gravio, V; Di Stefano, R; Martucci, G; Montini, L; Panarello, G; Polidori, P; Spanu, T; Vallecoccia, MS | 1 |
| Abbo, LM; Aragon, L; Bonomo, RA; Camargo, JF; Hujer, AM; Martinez, O; Nicolau, DP; Perez, F; Perez-Cardona, A; Rojas, LJ; Rosa, R; Rudin, SD; Tekin, A | 1 |
| Kim, JH; Kim, MJ; Kim, SB; Sohn, JW; Suh, JW; Yang, KS; Yoon, YK | 1 |
| Achard, MES; Anderson, GJ; Djoko, KY; Hancock, SJ; Harris, PN; Lo, AW; McEwan, AG; Miraula, M; Mitić, N; Paterson, DL; Peters, KM; Phan, MD; Prombhul, S; Schembri, MA; Schenk, G; Shafer, WM; Sidjabat, HE; Walsh, TR | 1 |
| Eumkeb, G; Evans, K; Hobbs, G; Nakouti, I; Teethaisong, Y | 1 |
| Horvath, E; Kazmierczak, KM; Sahm, DF; Wise, MG; Young, K | 1 |
| Abdul, W; Grigoriu, A; Smoke, SM; Vasant, D | 1 |
| Li, Y; Liu, J; Liu, Y; Shen, L; Yu, J; Zhu, W | 1 |
| Avril, C; Belmonte, O; Benoit-Cattin, T; Bertrand, X; Bonnin, RA; Cholley, P; de Montera, AM; Dortet, L; Filleul, L; Hocquet, D; Jaffar-Bandjee, MC; Leclaire, A; Lugagne, N; Martak, D; Miltgen, G; Naas, T; Roquebert, B; Subiros, M; Thouverez, M; Traversier, N | 1 |
| Bobola, V; Forbes, W; Frazier, W; Joyner, ML; Manning, CC | 1 |
| Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM | 1 |
| Izmailyan, S; Lawrence, K; Olesky, M; Solomkin, JS; Sway, A; Tsai, L | 1 |
| Carroll, KC; Chambers, KK; Goodman, K; Kazmi, AQ; Lewis, S; Milstone, AM; Opene, BNA; Simner, PJ; Tamma, PD; Wang, R; Workneh, M | 1 |
| Link, I; Loose, M; Naber, KG; Wagenlehner, FME | 1 |
| Caroline, C; Chien-Boon Lye, D; Choon-Kiat Tan, N; Ding, YY; Hsien-Xiong Lee, R; Lim, JP; Neo, HY; Pei-Ying Ho, E; Tan, KT; Wei-Han Ng, D | 1 |
| Choi, J; Dantas, G; Das, S; Gandra, S; Green, SJ; Harazin, M; McElvania, E; Singh, KS; Thomson, RB | 1 |
| Cury, AP; Duarte, AJDS; Girardello, R; Rossi, F | 1 |
| Jeyakanthan, J; Lopes, BS; Ramachandran, B | 1 |
| Allison, N; Crisostomo, C; Lynch, B; Padilla, M; Quach-Cu, J; Reinke, RA | 1 |
| Gasparetto, J; Telles, JP; Tuon, FF; Zequinão, T | 1 |
| Academia, EC; Jenrette, JE; McLaughlin, JM; Mueller, SW | 1 |
| Carevic, B; Carmeli, Y; Cohen-Percia, S; Fallach, N; Frenk, S; Harbarth, S; Hoffman, T; Kariv, Y; Klausner, J; Lellouche, J; Nutman, A; Temkin, E | 1 |
| Cai, J; Cui, W; Huang, J; Qian, Z; Song, F; Zhang, G; Zhang, K; Zheng, C; Zhou, F; Zhou, H | 1 |
| Burnham, CD; Eberly, AR; Heitman, AK; Jean, S; Schuetz, AN; Shannon, S; Wallace, MA | 1 |
| Critchley, IA; Dane, A; Eckburg, PB; Jain, A; Keutzer, T; Kwak, H; Melnick, D; Moore, G; Muir, L; Phelan, AM; Talley, AK; Walpole, S | 1 |
| Bruzzone, M; Ceppi, M; Piatti, G; Schito, AM; Vitale, A | 1 |
| Jung, EJ; Jung, Y; Kim, JY; Lee, J; Park, JJ; Seo, YB | 1 |
| Chibabhai, V; Nana, T; Perovic, O | 1 |
| Chen, DQ; Chen, EZ; Ling, JH; Liu, WT; Peng, C; Wang, LJ; Yang, L; Yuan, PB; Zhong, YX; Zhu, JH | 1 |
| Bai, Y; Fan, X; Fu, L; Tian, C; Wang, S; Xing, M; Zhao, Y | 1 |
| Abdulhemid Said, L; Muhsin, EA; Sajid Al-Jubori, S | 1 |
| Arimuthu, DA; Mazlan, SA; Shahar, S | 1 |
| Alzahrani, FM; Alzahrani, KJ; Amoa-Owusu, F; Bannah, V; Dayie, NTKD; Donkor, ES; Dwomoh, FP; Egyir, B; Halawani, IF; Kotey, FCN; Osei, MM | 1 |
| Ambrose, PG; Bhavnani, SM; Conde, H; Cotroneo, N; Friedrich, LV; Jones, S; VanScoy, BD | 1 |
| George Priya Doss, C; Gopikrishnan, M | 1 |
| Chang, YH; Hsu, CK; Huang, PY; Lai, CC; Liu, TH; Tang, HJ; Tsai, YW; Wu, JY | 1 |
| Feng, Y; Li, GB; Wang, S; Wang, X; Wu, S; Yang, Y; Zhu, K; Zong, Z | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
| Holmes, AH; Nasomsong, W; Panuvatvanich, B; Rawson, TM; Vasikasin, V | 1 |
| Ashcraft, D; Feehan, AK; Fogel, GB; Garcia-Diaz, J; Huston, C; Lain, B; Lamers, SL; Miele, L; Nolan, DJ; Pankey, G; Rose, R; Rosenthal, S; Velez-Climent, L | 1 |
19 review(s) available for carbapenems and ertapenem
| Article | Year |
|---|---|
Ertapenem: a new carbapenem.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials, Phase II as Topic; Drug Evaluation; Ertapenem; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Lactams; Microbial Sensitivity Tests | 2001 |
Properties and potential of ertapenem.
Topics: Bacteria; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Drug Resistance, Bacterial; Ertapenem; Half-Life; Humans; Lactams | 2003 |
Ertapenem, the first of a new group of carbapenems.
Topics: Animals; beta-Lactams; Carbapenems; Clinical Trials as Topic; Cross Infection; Ertapenem; Humans; Lactams | 2003 |
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Ertapenem; Humans; Lactams | 2004 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
Ertapenem: review of a new carbapenem.
Topics: Animals; beta-Lactams; Carbapenems; Drugs, Investigational; Ertapenem; Humans; Lactams | 2005 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
[Update on antimicrobial chemotherapy].
Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; France; Humans; Linezolid; Lipoglycopeptides; Minocycline; Oxazolidinones; Penicillins; Pyrimidines; Teicoplanin; Tigecycline | 2010 |
Carbapenems: past, present, and future.
Topics: Anti-Bacterial Agents; beta-Alanine; beta-Lactams; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Thienamycins | 2011 |
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pseudomonas aeruginosa | 2013 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Microbial Sensitivity Tests | 2020 |
Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gammaproteobacteria; Humans; Treatment Outcome | 2023 |
6 trial(s) available for carbapenems and ertapenem
| Article | Year |
|---|---|
Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.
Topics: Adult; Animals; beta-Lactams; Carbapenems; Carbon Radioisotopes; Ertapenem; Feces; Female; Humans; Lactams; Macaca mulatta; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Radioisotope Dilution Technique; Radiopharmaceuticals; Rats; Species Specificity; Tissue Distribution | 2004 |
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Middle Aged; Retrospective Studies; Sepsis; Survival Analysis; Treatment Outcome | 2016 |
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2017 |
Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Drug Resistance, Multiple; Ertapenem; Female; Humans; Italy; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Statistics, Nonparametric | 2017 |
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Data Interpretation, Statistical; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Tetracyclines; Young Adult | 2019 |
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Carbapenems; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Pyelonephritis; Urinary Tract Infections | 2022 |
121 other study(ies) available for carbapenems and ertapenem
| Article | Year |
|---|---|
Efficient one-pot synthesis of the 2-aminocarbonylpyrrolidin-4-ylthio-containing side chain of the new broad-spectrum carbapenem antibiotic ertapenem.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Chromatography, High Pressure Liquid; Combinatorial Chemistry Techniques; Ertapenem; Lactams; Molecular Structure; Pyrrolidines; Stereoisomerism | 2002 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2002 |
Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.
Topics: Adult; Aged; Area Under Curve; beta-Lactams; Carbapenems; Creatinine; Ertapenem; Female; Half-Life; Humans; Injections, Intravenous; Lactams; Male; Spectrophotometry, Ultraviolet | 2004 |
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Drug Resistance, Bacterial; Ertapenem; Humans; Lactams | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
Topics: beta-Lactams; Carbapenems; Culture Media, Serum-Free; Drug Resistance, Bacterial; Ertapenem; Lactams; Microbial Sensitivity Tests; Mutation; Porins; Pseudomonas aeruginosa | 2005 |
Quantification of the carbapenem antibiotic ertapenem in human plasma by a validated liquid chromatography-mass spectrometry method.
Topics: beta-Lactams; Calibration; Carbapenems; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Kidney Failure, Chronic; Mass Spectrometry; Reference Standards; Reproducibility of Results | 2006 |
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactams; Carbapenems; Drug Resistance, Microbial; Ertapenem; Gram-Negative Anaerobic Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inhibitory Concentration 50; Metronidazole; Microbial Sensitivity Tests | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spain; Thienamycins | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Humans; Klebsiella; Laboratories; Microbial Sensitivity Tests; United Kingdom | 2007 |
In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Ertapenem; Escherichia coli; Female; Hospitals, University; Humans; Infant; Infant, Newborn; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Turkey | 2008 |
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftazidime; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Imipenem; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Crystallography, X-Ray; Ertapenem; Imipenem; Meropenem; Molecular Structure; Solutions; Spectrum Analysis, Raman; Thienamycins | 2008 |
Presence of the KPC carbapenemase gene in Enterobacteriaceae causing bacteremia and its correlation with in vitro carbapenem susceptibility.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Microbial Sensitivity Tests; Middle Aged; Missouri; Predictive Value of Tests | 2009 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Hospitals; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2010 |
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Cyclotrons; Doripenem; Ertapenem; Fourier Analysis; Hydrogen Bonding; Indicators and Reagents; Kinetics; Mass Spectrometry; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Protein Conformation | 2010 |
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2010 |
Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Hospitals, University; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Porins; Taiwan | 2010 |
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Chi-Square Distribution; Confidence Intervals; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Thienamycins | 2011 |
New Delhi metallo-beta-lactamase from traveler returning to Canada.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Canada; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; India; Male; Microbial Sensitivity Tests; Prostatitis; Pyelonephritis; Travel; Urine | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 2011 |
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Utilization; Ertapenem; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Case-Control Studies; Drug Utilization; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Meropenem; Middle Aged; Risk Factors; Thienamycins | 2011 |
Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cross Infection; Ertapenem; Hand Disinfection; Hospitals, University; Humans; Incidence; Pseudomonas aeruginosa; Pseudomonas Infections; Regression Analysis | 2011 |
Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Interactions; Ertapenem; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; Formularies, Hospital as Topic; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; North Carolina; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2011 |
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Propensity Score; Thienamycins | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
Development of carbapenem resistance during therapy for non-typhoid Salmonella infection.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Ertapenem; Feces; Female; Humans; Microbial Sensitivity Tests; Plasmids; Point Mutation; Porins; RNA, Bacterial; Salmonella Infections; Salmonella typhimurium; Urinary Tract Infections; Wound Infection | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Logistic Models; Male; Middle Aged; Molecular Epidemiology; Multivariate Analysis; Risk Factors; Singapore; Treatment Outcome; Young Adult | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Linear Models; Meropenem; Microbial Sensitivity Tests; Prevalence; Prospective Studies; Taiwan; Thienamycins | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010
Topics: Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Prevalence; Prospective Studies | 2012 |
Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Utilization; Ertapenem; Hospitals; Humans; Pseudomonas aeruginosa; Queensland | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Rapid selection of carbapenem-resistant Pseudomonas aeruginosa by clinical concentrations of ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Ertapenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Selection, Genetic | 2013 |
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Ertapenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Treatment Outcome | 2013 |
Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Porins; Trans-Activators | 2013 |
Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Time Factors | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Use of outpatient parenteral antimicrobial therapy for transrectal ultrasound-guided prostate biopsy prophylaxis in the setting of community-associated multidrug-resistant Escherichia coli rectal colonization.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Hospitalization; Humans; Image-Guided Biopsy; Infusions, Parenteral; Male; Middle Aged; Outpatients; Prevalence; Prospective Studies; Prostate; Prostatitis; Rectum; Ultrasonography, Interventional | 2014 |
Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Disease Susceptibility; Drug Resistance, Multiple; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Providencia; Thienamycins | 2014 |
Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests | 2014 |
Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Vietnam | 2014 |
Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2).
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Line; Ertapenem; HeLa Cells; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Binding; Thienamycins | 2014 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Taiwan; Thienamycins | 2015 |
Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Hypoalbuminemia; Israel; Middle Aged; Prospective Studies; Risk Factors | 2015 |
Identification of New Natural CphA Metallo-β-Lactamases CphA4 and CphA5 in Aeromonas veronii and Aeromonas hydrophila Isolates from Municipal Sewage in Central Italy.
Topics: Aeromonas hydrophila; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Imipenem; Italy; Molecular Sequence Data; Point Mutation; Sewage; Thienamycins | 2015 |
Role of efflux pumps inhibitor in decreasing antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in North India.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Genotype; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Polymerase Chain Reaction; Tigecycline | 2015 |
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Ertapenem; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2016 |
Camellia sinensis Ameliorates the Efficacy of Last Line Antibiotics Against Carbapenem Resistant Escherichia coli.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactams; Camellia sinensis; Carbapenems; Colistin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Flavonoids; Free Radical Scavengers; Meropenem; Microbial Sensitivity Tests; Minocycline; Phytochemicals; Plant Extracts; Plant Leaves; Thienamycins; Tigecycline | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, epidemiology, and risk factors.
Topics: Aged; Antimicrobial Stewardship; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Cefepime; Colombia; Cross Infection; Diagnosis-Related Groups; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Risk Factors; Tertiary Care Centers | 2017 |
Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Kidney Transplantation; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Surgical Wound Infection; Thienamycins | 2016 |
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Phenotype; Thienamycins; Turkey | 2016 |
Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing β-lactamase KPC-2 from China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; China; DNA, Bacterial; Ertapenem; Female; Genotype; Hospitals; Humans; Hydrolysis; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2016 |
Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clinical Laboratory Techniques; Enterobacter aerogenes; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Comparison of the Modified-Hodge test, Carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity; Thienamycins | 2016 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Hospitals; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Thienamycins | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
Occurrence of bla
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Conjugation, Genetic; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; India; Plasmids | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Thienamycins | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
Editorial Comment.
Topics: Biopsy; Carbapenems; Ertapenem; Humans; Male; Prospective Studies; Prostate | 2017 |
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.
Topics: beta-Lactams; Carbapenems; Ertapenem; Imipenem; Meropenem; Molecular Dynamics Simulation; Mycobacterium tuberculosis; Principal Component Analysis; Thienamycins | 2017 |
Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Fosfomycin; Humans; Intestines; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Postoperative Complications; Precision Medicine | 2017 |
The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Pyelonephritis; Republic of Korea; Retrospective Studies; Risk Factors; Treatment Outcome | 2018 |
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants.
Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Coordination Complexes; Copper; Ertapenem; Escherichia coli; Humans; Ions; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2018 |
A nitrocefin disc supplemented with ertapenem for rapid screening of carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Microbial Sensitivity Tests; Sensitivity and Specificity | 2018 |
Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Electrophoresis, Polyacrylamide Gel; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutation; Porins | 2018 |
Effect of Carbapenem Selection on Drug Acquisition Costs and Carbapenem Resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; United States | 2019 |
Rapid detection of carbapenemase activity of Enterobacteriaceae isolated from positive blood cultures by MALDI-TOF MS.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Ertapenem; Humans; Hydrolysis; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Outbreak of IMI-1 carbapenemase-producing colistin-resistant Enterobacter cloacae on the French island of Mayotte (Indian Ocean).
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Colistin; Comoros; Disease Outbreaks; Electrophoresis, Gel, Pulsed-Field; Enterobacter cloacae; Enterobacteriaceae Infections; Ertapenem; Female; Genome, Bacterial; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Young Adult | 2018 |
Modeling Ertapenem: the impact of body mass index on distribution of the antibiotic in the body.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Body Mass Index; Body Weight; Carbapenems; Computer Simulation; Drug Administration Schedule; Ertapenem; Female; Humans; Male; Models, Theoretical; Obesity; Thinness | 2019 |
Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Diagnostic Errors; Ertapenem; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Random Amplified Polymorphic DNA Technique | 2019 |
Evaluation of the Direct MacConkey Method for Identification of Carbapenem-Resistant Gram-Negative Organisms from Rectal Swabs: Reevaluating Zone Diameter Cutoffs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Rectum; ROC Curve; Sensitivity and Specificity | 2019 |
Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Fosfomycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Rifampin; Urinary Tract Infections | 2019 |
Higher rates of carbapenem-related seizures in older hospitalised adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Logistic Models; Male; Meropenem; Seizures; Singapore | 2020 |
Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Porins | 2020 |
KPC-producing Enterobacterales with uncommon carbapenem susceptibility profile in Vitek 2 system.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Gammaproteobacteria; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2020 |
Molecular docking, dynamics and free energy analyses of
Topics: Acinetobacter baumannii; Ampicillin; beta-Lactamases; Carbapenems; Catalytic Domain; Computer Simulation; Doripenem; Ertapenem; Hydrolysis; Meropenem; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation | 2020 |
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Ertapenem; Imipenem; Meropenem; Wastewater; Water Purification | 2020 |
Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Emergency Service, Hospital; Ertapenem; Humans; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sulbactam | 2022 |
The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generation-cephalosporin-resistant Enterobacterales after colorectal surgery.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefuroxime; Cephalosporins; Colorectal Surgery; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Ertapenem; Humans; Metronidazole; Spectroscopy, Fourier Transform Infrared | 2021 |
Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial
Topics: Adult; Aged; Bacteremia; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Development and Validation of a Novel Anaerobic Carbapenem Inactivation Method (Ana-CIM) for the Detection of Carbapenemase Production in Bacteroides fragilis.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacterial Infections; Bacterial Proteins; Bacteroides fragilis; beta-Lactamases; Carbapenems; Ertapenem; Humans; Microbial Sensitivity Tests; Reproducibility of Results | 2022 |
Improved isolation of carbapenem-resistant Enterobacterales on selective-differential media extending the incubation time: an approach to strengthen the antimicrobial surveillance from rectal swabs.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prospective Studies | 2022 |
Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Humans; Klebsiella pneumoniae; Retrospective Studies | 2022 |
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Oxacillin | 2022 |
Proteomics profiling of ertapenem challenged major porin deficient carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Antioxidants; ATP-Binding Cassette Transporters; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Proteomics | 2022 |
Whole genome sequencing of OXA-232-producing
Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprofloxacin; DNA Transposable Elements; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis; Virulence; Virulence Factors; Whole Genome Sequencing | 2022 |
Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Prevalence | 2022 |
Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neurotoxicity Syndromes; Renal Dialysis; Renal Insufficiency, Chronic | 2022 |
Phenotypic and genotypic detection of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Accra, Ghana.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross-Sectional Studies; Ertapenem; Escherichia coli; Ghana; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans | 2023 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |
Characterization of a novel carbapenem-hydrolysing β-lactamase OXA-1041 in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation | 2023 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |
Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation cephalosporin-resistant Enterobacterales bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Ertapenem; Escherichia coli; Humans; Propensity Score; Prospective Studies; Shock, Septic | 2023 |
Comparing antimicrobial resistant genes and phenotypes across multiple sequencing platforms and assays for Enterobacterales clinical isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Ertapenem; Genotype; Phenotype | 2023 |